Larazotide vs TB-500.

Larazotide (larazotide acetate, research code AT-1001) is a synthetic eight-amino-acid peptide investigated as an oral, gut-restricted therapy for celiac disease. It was designed to act locally in the small intestine rather than being absorbed systemically. The concept was to add a first non-dietary treatment for patients who still have symptoms despite a gluten-free diet. It advanced through Phase 2 and into Phase 3 development but is not approved by the FDA or any major regulator. It is categorized under healing because its target is intestinal barrier repair and integrity.

TB-500 is a synthetic peptide sold for research use and widely marketed as "thymosin beta-4 (Tβ4)." Naturally occurring Tβ4 is a 43-amino-acid, ~4.9 kDa actin-sequestering peptide found in nearly all mammalian cells and at high concentration in platelets and wound fluid. Notably, many products labeled "TB-500" are actually a shorter synthetic fragment built around the active actin-binding motif (LKKTET/LKKTETQ) rather than the full-length Tβ4 molecule, so the name is used loosely in the research-chemical market and the exact identity of a given vial is often unverified.

Larazotide is a tight-junction regulator, often described as a zonulin antagonist. In celiac disease, gluten exposure is associated with increased release of zonulin and loosening of the tight junctions between intestinal epithelial cells, allowing gluten peptides to cross the barrier and drive immune activation. Larazotide is proposed to promote tight-junction assembly and reduce paracellular permeability (leaky gut), thereby limiting gluten peptide entry and downstream inflammation. It is intended to work in the gut lumen, which fits its minimal systemic absorption. The precise molecular target and the physiological role of zonulin itself remain areas of scientific debate.

The best-characterized function of thymosin beta-4 is binding monomeric G-actin in a 1:1 complex, acting as the principal intracellular actin-sequestering peptide that buffers the pool of unpolymerized actin and thereby modulates cytoskeletal assembly, cell shape, and migration. Through the LKKTET motif and downstream signaling, Tβ4 has been reported in preclinical models to promote keratinocyte and endothelial cell migration, angiogenesis, anti-inflammatory and anti-apoptotic effects, and activation of integrin-linked kinase (ILK)/Akt and laminin-5 pathways relevant to wound repair. These mechanisms are mostly established in cell and animal systems; the degree to which a synthetic LKKTET-type fragment reproduces full-length Tβ4 biology is not firmly established.

Mid-stage data were encouraging but the definitive trial did not succeed. In a Phase 2b randomized, double-blind, placebo-controlled trial (Leffler et al., Gastroenterology, 2015; 342 patients with persistent symptoms despite a gluten-free diet), low-dose larazotide reduced patient-reported symptoms versus placebo, with the lowest dose showing the clearest signal. On the strength of such results the program advanced to a large Phase 3 trial (CeD-2001) run by 9 Meters Biopharma. That Phase 3 study was halted after an interim analysis indicated it was unlikely to meet its primary endpoint, the change from baseline in celiac symptom severity, effectively ending the program. In short: positive Phase 2b data did not translate into a successful Phase 3 result, and larazotide is not an approved therapy. Several features of the earlier evidence look different in hindsight. The Phase 2b result was strongest at the lowest dose tested, without a conventional dose-response relationship, a pattern that is difficult to interpret mechanistically and that often does not reproduce. Primary endpoints across the program were patient-reported symptom scores rather than histology or objective mucosal healing, and symptom scores in celiac disease are noisy and prone to large placebo responses. Supporting biology exists outside these trials: larazotide acetate promoted recovery of ischemia-injured porcine jejunum through repair of tight junctions (PLoS One, 2021), and reviews of celiac pharmacotherapy place tight-junction regulation among several strategies that have been tried without yet producing an approved drug (European Journal of Pharmacology, 2021). The comparison that matters is with existing management. A strict lifelong gluten-free diet remains the only established treatment for celiac disease, supported by decades of clinical experience and by histologic and serologic recovery in patients who adhere to it. No drug has been approved as an adjunct or replacement. Larazotide reached the last stage of testing and failed there, so the honest summary is that the leading non-dietary candidate did not demonstrate benefit when tested at confirmatory scale.

Human evidence comes almost entirely from the full-length Tβ4 molecule developed pharmaceutically by RegeneRx and partners, not from research-chemical "TB-500." Topical Tβ4 (RGN-137) was tested in completed Phase 2 dermal-wound trials including a randomized, placebo-controlled study in venous stasis ulcers (ClinicalTrials.gov NCT00832091), and ophthalmic Tβ4 (RGN-259) has advanced to Phase 3 for neurotrophic keratopathy (e.g., the SEER-2 trial, NCT05555589). Preclinical support for dermal, corneal, and cardiac repair is substantial and replicated across labs, as reviewed by Kleinman and Sosne (Vitamins and Hormones, 2016). However, there are no controlled human trials of injectable "TB-500" as sold in the peptide market for musculoskeletal healing, tendon/ligament injury, or athletic recovery; those uses rest on animal data and extrapolation, and the human-vs-preclinical gap is wide.

Across trials larazotide was generally well tolerated, consistent with a peptide that acts locally in the gut and is minimally absorbed. Reported adverse events were typically mild and gastrointestinal, such as abdominal discomfort, nausea, or headache, and were often similar between drug and placebo groups. Minimal systemic absorption limits the plausibility of effects outside the intestinal lumen, and no distinctive organ toxicity emerged as a program-stopping signal; the Phase 3 trial was discontinued for likely futility on efficacy, not for safety. Because development stopped before approval, there is no long-term real-world safety dataset in a broad treated population. Clinical trial exposure was limited in duration and confined to selected participants who met entry criteria, so effects of use over years, in children, in pregnancy, in older patients with comorbidities, or alongside common medications were never characterized. There is no post-marketing pharmacovigilance stream because there is no marketed product, and no regulator has reviewed a complete safety dossier. Anything sold as larazotide outside a clinical trial carries the separate risks of unapproved supply: no verified identity or purity, no batch testing, no good manufacturing practice oversight, and no adverse-event reporting. There is also an indirect risk specific to celiac disease, since any product presented as protection against gluten exposure could encourage relaxation of the gluten-free diet, which remains the only established management and the only intervention shown to allow mucosal recovery. This entry is educational only and is not a recommendation to obtain or use the compound, which is not an approved medicine.

There is no established human safety profile for research-chemical "TB-500"; it is not a licensed drug and is not manufactured to pharmaceutical quality, so identity, purity, sterility, and endotoxin content of marketed vials are unverified. Pharmaceutical full-length Tβ4 has been reasonably well tolerated in controlled topical and ophthalmic trials, but those findings do not transfer to unregulated injectable products. A recurring theoretical concern is that a peptide promoting angiogenesis and cell migration could be undesirable in the setting of occult malignancy, though this is not established as a clinical harm. Contamination, dosing errors, and injection-related risks are the most concrete real-world hazards.

Larazotide is investigational and is not approved by the FDA or EMA for celiac disease or any other indication. It reached Phase 3, but the pivotal CeD-2001 trial was discontinued for likely futility on its primary endpoint. Any product sold as larazotide outside of a clinical trial is not an approved drug.

TB-500/thymosin beta-4 is not approved by the FDA or EMA for any indication; full-length Tβ4 remains investigational (RegeneRx/ReGenTree ophthalmic and dermal programs), and material sold as "TB-500" is research-use-only and not a dietary supplement or medicine. It is prohibited in sport at all times by the World Anti-Doping Agency under class S2 (peptide hormones, growth factors, related substances and mimetics).